These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Newport DJ; Heim C; Owens MJ; Ritchie JC; Ramsey CH; Bonsall R; Miller AH; Nemeroff CB Neuropsychopharmacology; 2003 Mar; 28(3):569-76. PubMed ID: 12629539 [TBL] [Abstract][Full Text] [Related]
43. [Corticotropin releasing factor as an aid in the diagnosis of Cushing syndrome]. Pirich K; Vierhapper H; Nowotny P Wien Klin Wochenschr; 1985 Nov; 97(21):806-8. PubMed ID: 2998101 [TBL] [Abstract][Full Text] [Related]
44. Corticotropin-releasing factor (CRF) stimulation test in normal subjects and patients with Cushing's syndrome. Zacharieva S; Matrosov P; Stoeva I; Kirilov G Exp Clin Endocrinol; 1989 Apr; 93(1):19-28. PubMed ID: 2544435 [TBL] [Abstract][Full Text] [Related]
45. Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. Kemink L; Pieters G; Hermus A; Smals A; Kloppenborg P J Clin Endocrinol Metab; 1994 Sep; 79(3):887-9. PubMed ID: 8077377 [TBL] [Abstract][Full Text] [Related]
46. Normal and abnormal regulation of beta-msh in man. Abe K; Nicholson WE; Liddle GW; Orth DN; Island DP J Clin Invest; 1969 Aug; 48(8):1580-5. PubMed ID: 4307702 [TBL] [Abstract][Full Text] [Related]
47. Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing's syndrome due to pituitary adenoma. Letizia C; Di Iorio R; De Toma G; Marinoni E; Cerci S; Celi M; Subioli S; D'Erasmo E Metabolism; 2000 Jun; 49(6):760-3. PubMed ID: 10877203 [TBL] [Abstract][Full Text] [Related]
48. [Is it possible to predict the development of Nelson's syndrome in Cushing's disease after bilateral adrenalectomy?]. Horký K; Kanka J; Gregorová I; Tomsová Z; Dvoráková J Cas Lek Cesk; 1990 May; 129(21):645-9. PubMed ID: 2164450 [TBL] [Abstract][Full Text] [Related]
49. Distribution and characterization of immunoreactive corticotropin-releasing factor in human tissues. Suda T; Tomori N; Tozawa F; Mouri T; Demura H; Shizume K J Clin Endocrinol Metab; 1984 Nov; 59(5):861-6. PubMed ID: 6332825 [TBL] [Abstract][Full Text] [Related]
50. Somatomedin levels in cerebrospinal fluid from adults with pituitary disorders. Bäckström M; Hall K; Sara V Acta Endocrinol (Copenh); 1984 Oct; 107(2):171-8. PubMed ID: 6388207 [TBL] [Abstract][Full Text] [Related]
51. Bilateral and simultaneous sinus petrosus inferior catheterization in patients with Cushing's syndrome: plasma-immunoreactive-ACTH-concentrations before and after administration of CRF. Schulte HM; Allolio B; Günther RW; Benker G; Windeck R; Winkelmann W; Reinwein D Horm Metab Res Suppl; 1987; 16():66-7. PubMed ID: 2832295 [TBL] [Abstract][Full Text] [Related]
52. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. Gold PW; Loriaux DL; Roy A; Kling MA; Calabrese JR; Kellner CH; Nieman LK; Post RM; Pickar D; Gallucci W N Engl J Med; 1986 May; 314(21):1329-35. PubMed ID: 3010108 [TBL] [Abstract][Full Text] [Related]
53. Corticotropin-releasing hormone and adrenocorticotropic hormone concentrations in cerebrospinal fluid of dogs with pituitary-dependent hyperadrenocorticism. Van Wijk PA; Rijnberk A; Croughs RJ; Voorhout G; Sprang EP; Mol JA Endocrinology; 1992 Dec; 131(6):2659-62. PubMed ID: 1332844 [TBL] [Abstract][Full Text] [Related]
54. Incidence of Nelson's syndrome and residual adrenocortical function in patients of Cushing's disease after bilateral adrenalectomy. Misra D; Kapur MM; Gupta DK J Assoc Physicians India; 1994 Apr; 42(4):304-5. PubMed ID: 7860549 [TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. McLean SA; Williams DA; Stein PK; Harris RE; Lyden AK; Whalen G; Park KM; Liberzon I; Sen A; Gracely RH; Baraniuk JN; Clauw DJ Neuropsychopharmacology; 2006 Dec; 31(12):2776-82. PubMed ID: 16936702 [TBL] [Abstract][Full Text] [Related]
56. Absence of detectable immunoreactive alpha melanocyte stimulating hormone in plasma in various types of Cushing's disease. Croughs RJ; Thijssen JH; Mol JA J Endocrinol Invest; 1991 Mar; 14(3):197-200. PubMed ID: 1649212 [TBL] [Abstract][Full Text] [Related]
57. Immunoreactive corticotropin-releasing factor is present in human maternal plasma during the third trimester of pregnancy. Sasaki A; Liotta AS; Luckey MM; Margioris AN; Suda T; Krieger DT J Clin Endocrinol Metab; 1984 Oct; 59(4):812-4. PubMed ID: 6332823 [TBL] [Abstract][Full Text] [Related]
58. [TREATMENT OF STATES OF HYPOGONADISM]. D ALMEIDA JN Gaz Med Port; 1963; 16():333-57. PubMed ID: 14075350 [No Abstract] [Full Text] [Related]
59. Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease. Krieger DT; Liotta AS; Suda T; Goodgold A; Condon E J Clin Endocrinol Metab; 1979 Apr; 48(4):566-71. PubMed ID: 219000 [No Abstract] [Full Text] [Related]
60. Characterization of immunoreactive corticotropin and corticotropin-releasing factor in human adrenal and ovarian tumours. Suda T; Tomori N; Yajima F; Odagiri E; Demura H; Shizume K Acta Endocrinol (Copenh); 1986 Apr; 111(4):546-52. PubMed ID: 3010623 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]